Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations

NCT04418167 is registered in ClinicalTrials.gov with JS InnoPharm, LLC as lead sponsor.

NCT NCT04418167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04418167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
Lead sponsor
JS InnoPharm, LLC
Phase
Phase 1
Overall status
Suspended
Start date
June 18, 2020
Completion date
December 31, 2025
Enrollment
71 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors